3.95
-0.13(-3.19%)
Currency In USD
| Previous Close | 4.08 |
| Open | 4.06 |
| Day High | 4.06 |
| Day Low | 3.86 |
| 52-Week High | 12.46 |
| 52-Week Low | 1.15 |
| Volume | 36,243 |
| Average Volume | 3.02M |
| Market Cap | 27.62M |
| PE | -2.14 |
| EPS | -1.85 |
| Moving Average 50 Days | 3.67 |
| Moving Average 200 Days | 2.28 |
| Change | -0.13 |
If you invested $1000 in Minerva Neurosciences, Inc. (NERV) 10 years ago, it would be worth $101.91 as of December 14, 2025 at a share price of $3.95. Whereas If you bought $1000 worth of Minerva Neurosciences, Inc. (NERV) shares 5 years ago, it would be worth $186.32 as of December 14, 2025 at a share price of $3.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
GlobeNewswire Inc.
Nov 19, 2025 1:30 PM GMT
BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appoi
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
GlobeNewswire Inc.
Oct 21, 2025 12:00 PM GMT
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path forward for roluperidone’s clinical development and NDA resubmission.Further $40 mil
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
GlobeNewswire Inc.
Nov 05, 2024 12:30 PM GMT
BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported busi